Page Image

Mantle Cell Lymphoma

The latest news, research, and perspectives in mantle cell lymphoma (MCL). In MCL, a malignant B lymphocyte in the outer edge, or mantle zone, of a lymph node follicle grows uncontrollably, resulting in the accumulation of lymphoma cells.

Advertisement
Advertisement
Melissa BadamoAcute Lymphoblastic Leukemia | March 14, 2025
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
Andrew MorenoAggressive B-Cell Lymphoma | March 14, 2025
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
Andrew MorenoFollicular Lymphoma | February 26, 2025
Clinical evaluations of this bispecific antibody as monotherapy or in polytherapy for B-cell non-Hodgkin lymphomas continue.
Andrew MorenoFollicular Lymphoma | March 14, 2025
This new approval adds upon the agent's indications for relapsed or refractory DLBCL and other large B-cell lymphomas.
Melissa BadamoMantle Cell Lymphoma | February 21, 2025
Dr. Phillips discussed the phase II TRIANGLE study, the shifting role of HSCT, and unmet needs in high-risk patients.
Melissa BadamoMantle Cell Lymphoma | February 19, 2025
CAR22 therapy demonstrated an ORR of 100% and a complete response rate of 83% in six patients with MCL or FL.
Andrew MorenoAggressive B-Cell Lymphoma | March 14, 2025
Approved for adults ineligible for autologous transplant or CAR T-cell therapy following at least two systemic therapies.
Blood Cancer TalksChronic Lymphocytic Leukemia | January 31, 2025
David Russler-Germain, MD, PhD, joins the hosts of “Blood Cancer Talks” to highlight research in lymphoma and CLL.
Andrew MorenoT-Cell Lymphoma | January 30, 2025
Therapy also in development for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.
Andrew MorenoAggressive B-Cell Lymphoma | January 29, 2025
The single-slide test helps clinicians differentiate more than 60 subtypes of these diseases from normal immune response.
Blood Cancers Today Staff WritersMantle Cell Lymphoma | January 27, 2025
Researchers are launching a new clinical trial that will evaluate the combination of glofitamab with pirtobrutinib in MCL.
Andrew MorenoTransplantation & Cellular Therapy | January 23, 2025
The therapies are under development for EBV-positive PTLD, non-Hodgkin lymphoma, and systemic lupus erythematosus.
Melissa BadamoMantle Cell Lymphoma | January 17, 2025
Acalabrutinib was previously granted priority review in October 2024 based on results from the phase 3 ECHO trial.
Nichole TuckerFollicular Lymphoma | January 13, 2025
Relmacabtagene autoleucel is an anti-CD19 chimeric antigen receptor T-cell product
Andrew MorenoAcute Lymphoblastic Leukemia | January 10, 2025
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
Nichole TuckerMantle Cell Lymphoma | January 9, 2025
The phase 1b study of CAR22 is ongoing, and investigators are currently looking to enroll more patients.
Xu Ji, PhD, MSPHVideo Insights | January 3, 2025
A database study has identified an association between disease stage at lymphoma diagnosis and time of Medicaid enrollment.
Nichole TuckerMantle Cell Lymphoma | December 20, 2024
Updated results from the phase 3 ECHO trial were presented at ASH 2024.
Julie GouldMantle Cell Lymphoma | December 20, 2024
Future research must focus on developing more effective therapies to address the unmet needs of this high-risk MCL.
Nichole TuckerFollicular Lymphoma | December 12, 2024
Results from the phase 1 ENABLE-1 study show complete responses comparable to commercial CAR Ts in B-cell NHL.
Nichole TuckerChronic Lymphocytic Leukemia | December 12, 2024
CTX112, a next-generation allogeneic CRISPR-Cas9–engineered showing encouraging results in B-cell malignancies.